MiNK Therapeutics Inc (NAS:INKT)

Q1 2026 Mink Therapeutics Inc Earnings Call Transcript

May 15, 2026 / 12:30 PM GMT

Release Date Price: $10.72 (+2.00%)

Transcript 10-Q8-K

Key Points

Positve

MiNK Therapeutics Inc (INKT) presented data at four major international scientific meetings, showcasing their progress in pulmonary fibrosis, refractory gastric cancer, and severe lung injury.
The company has initiated a randomized Phase II clinical trial for their Agent 797 in combination with standard care for severe acute lung injury and respiratory distress, with plans for a seamless Phase 2/3 pathway.
MiNK Therapeutics Inc (INKT) has developed a scalable manufacturing process for their INKT cell therapies, allowing for efficient production and distribution, even under challenging conditions like wartime in Ukraine.
The collaboration with SeeFurther to advance PRAME-targeted INKT cell therapy for pediatric cancers provides non-dilutive support and potential commercial benefits.
The company maintains a strong cash position, providing operational runway for at least the next 12 months, supporting ongoing clinical trials and development programs.

Negative

Despite promising data, the development of medicines for conditions like ARDS has historically been challenging due to biologic heterogeneity and complexity.
The company faces significant risks and uncertainties related to clinical development, regulatory approvals, and commercial plans, as highlighted in their forward-looking statements.
MiNK Therapeutics Inc (INKT) reported a net loss of approximately $2.7 million for the first quarter of 2026, reflecting ongoing financial challenges.
The success of their INKT cell therapies is contingent on the ability to demonstrate efficacy in diverse and complex disease environments, which remains a significant hurdle.
The company's reliance on partnerships and collaborations, such as with SeeFurther and Immunity Bio, introduces potential dependency risks on external entities for successful program advancement.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

INKT.OQ - Mink Therapeutics Inc
Q1 2026 Mink Therapeutics Inc Earnings Call
May 15, 2026 / 12:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning and welcome to Mink Therapeutics, first quarter 2026 conference call and webcast. All participants will be in a listen-only mode until their question-and-answer session. Please note this event is being recorded and I would now like to turn the conference over to Stephanie from Mink Investor Relations. Stephanie, please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, operator, and thank you all for joining us today. Today's call is being webcast and will be available on our website for a replay. I'd like to remind you that this call will include

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.